By Nana O 
Immune therapy has revolutionized cancer treatment, offering new hope to patients by harnessing the body’s own defenses to combat malignant cells. However, a significant challenge persists: many tumors possess an uncanny ability to evade these powerful therapies by closely mimicking healthy tissue. This inherent resemblance allows cancer cells to effectively hide in plain sight, frustrating the immune system’s surveillance mechanisms and leading to treatment resistance. The ongoing quest to overcome this immune evasion has been a central focus of cancer research, pushing the boundaries of scientific understanding and therapeutic innovation.
Now, a groundbreaking discovery by researchers at the University of California, San Francisco (UCSF) has illuminated a novel pathway to identify and target these elusive tumors. Their work, published in the prestigious journal Nature on February 19th, reveals that certain aggressive cancers, including the notoriously difficult-to-treat brain cancer known as glioma, produce unique, "jumbled" proteins that make them distinctly recognizable. These newly identified cancer-specific proteins, termed antigens, represent a significant leap forward in the development of potent immunotherapies capable of recognizing and eradicating even the most recalcitrant tumors.
The study, bolstered by crucial funding from the National Institutes of Health, delved into the intricate molecular machinery of cancer cells, specifically focusing on RNA splicing. RNA splicing is a fundamental biological process that dictates how messenger RNA (mRNA) molecules—the blueprints for protein synthesis—are assembled from smaller genetic segments. The UCSF team discovered that in a variety of cancers, including those affecting the brain, prostate, liver, and colon, tumor cells engage in aberrant RNA splicing. This process results in the creation of novel mRNA sequences, which in turn give rise to entirely new protein variants, or antigens, that are never found in healthy tissues.
The significance of these findings lies in the fact that some of these newly generated RNAs produce antigens that are displayed on the surface of tumor cells. This surface presentation acts as a critical "beacon," providing a clear entry point for immunotherapies. By engineering immune T-cells to specifically recognize these unique cancer antigens, the researchers were able to demonstrate their remarkable ability to destroy glioma cells in laboratory settings. This discovery has the potential to dramatically expand the repertoire of targets available for immunotherapy, thereby broadening treatment options for patients battling difficult-to-treat cancers.
"We believe these initial antigens could be actionable in the near future, paving the way for novel therapies for glioma patients," stated Hideho Okada, MD, PhD, professor of neurosurgery at UCSF and co-corresponding author of the paper. "However, this is merely the tip of the iceberg, and we are eager to explore the vast amount of data we have generated to uncover many more such targets."
The Hunt for Neoantigens: A Shift in Immunotherapy Strategy
For years, precision medicine has largely focused on two main strategies: drugs that target specific genetic mutations driving cancer growth, or immunotherapies that empower the immune system to identify and attack cancer-related antigens. While these approaches have yielded significant successes, a substantial hurdle remains for tumors that lack detectable mutations or possess antigens that are not sufficiently distinct from those found in healthy cells. This scarcity of reliable targets limits the efficacy of current treatments for a significant portion of cancer patients.
"One of the primary reasons we suspect many glioma therapies fall short is their tendency to target only a single aspect of the tumor," explained Joe Costello, PhD, professor of neurosurgery at UCSF and co-corresponding author. "The remainder of the tumor can then escape treatment unscathed. These newly discovered antigens offer a way to overcome this major challenge posed by the inherent heterogeneity of brain tumors."
The UCSF research team, led by Darwin Kwok, PhD, embarked on a comprehensive investigation into RNA splicing as a potential source of novel cancer targets. While many contemporary cancer therapies are designed to exploit unique DNA mutations within tumors, the researchers hypothesized that altered RNA splicing could also give rise to entirely new, cancer-specific antigens.
Kwok, a former PhD graduate of the Okada and Costello labs and a current UCSF medical student, meticulously analyzed vast datasets from The Cancer Genome Atlas, a monumental project by the National Cancer Institute. His focus was on identifying uniquely spliced mRNA sequences that were consistently present across multiple biopsies within individual tumors and across a diverse patient population. These analyses spanned a wide range of cancer types, including prostate, liver, colon, stomach, kidney, and lung cancers.
To further refine their search, the team collaborated with the UCSF Brain Tumor Center. They examined mRNA profiles from glioma samples donated by 51 UCSF patients, carefully collecting up to ten biopsies from different regions within each tumor. This detailed sampling allowed them to meticulously track the origin of each biopsy and identify any unusual mRNA patterns.
A Reservoir of Novel Targets Identified
Through this extensive and systematic analysis, the researchers identified nearly 1,000 cancer-specific mRNA sequences. Crucially, these sequences were found to be common across different tumors, cancer types, and patients, and had never been previously documented in scientific literature. Furthermore, rigorous checks confirmed that these novel mRNAs were entirely absent in healthy tissue samples, solidifying their status as bona fide cancer-specific markers.
The journey from identifying a novel mRNA to developing a viable immunotherapy target is a multi-step process. Not all mRNAs translate into proteins, not all proteins are presented as antigens on the cell surface, and not all surface antigens are recognized by the immune system. Therefore, the UCSF team employed sophisticated computational modeling to predict which of these newly identified mRNAs had the highest probability of progressing through this pathway to become effective immunotherapy targets.
This predictive modeling narrowed down the initial list of nearly 1,000 cancer-specific mRNAs to 32 promising antigen candidates. These candidates were all products of alternative RNA splicing in cancer cells and showed potential for therapeutic intervention. The researchers then selected the top four candidates for more in-depth experimental validation. These four antigens were chosen because they exhibited structural similarities to other known antigens that are capable of eliciting a strong immune response.
Engineering Immunity: From Discovery to Potential Therapy
The subsequent experimental phase involved programming cells to display these four antigen candidates. These engineered cells were then exposed to immune cells, specifically T-cells, harvested from healthy donors. The critical observation was that the natural immune cells from these donors possessed receptors that could reliably detect and bind to the cancerous antigens. This finding was a pivotal moment, confirming that these newly discovered antigens were indeed recognizable by the immune system, a crucial prerequisite for developing effective immunotherapies.
The likelihood of finding such complementary immune receptors in donated blood was exceedingly low, described by Dr. Okada as "like one in five or 10 million." Yet, against these odds, the team achieved remarkable success. For two of the top four antigens, they identified compatible immune receptors present in two different blood donors. This "strike gold" moment provided the essential components needed to engineer a targeted immune response.
Building upon this discovery, the researchers then engineered laboratory-derived T-cells to express these identified immune receptors. These specially trained T-cells were subsequently unleashed upon glioma cells in a controlled laboratory environment. The results were decisive: the engineered T-cells effectively recognized and rapidly eliminated the cancer cells, demonstrating the potent therapeutic potential of this novel approach.
The Road Ahead: Clinical Translation and Broader Implications
The success in laboratory settings marks a significant milestone, but the ultimate goal is to translate these findings into tangible benefits for patients. The UCSF team is currently advancing this research into animal models of cancer. If these preclinical studies prove successful, they aim to expedite the translation of these promising therapies to human clinical trials. The potential impact extends beyond the initial four antigens; the researchers have identified an additional 28 promising candidates from this study alone, and the vast datasets generated suggest the existence of countless more.
The precise biological reasons behind the widespread production of these specific "jumbled" proteins across various cancers remain a subject of ongoing investigation. It is possible that this phenomenon is an inherent, albeit unexpected, consequence of cancer biology. Regardless of the underlying cause, this discovery has undeniably opened a new frontier in the fight against cancer.
"This advancement for cancer patients represents the pinnacle of collaborative effort at UCSF, encompassing everything from sophisticated computational modeling to rigorous laboratory validation and cutting-edge techniques in brain surgery," Dr. Okada emphasized. "This is precisely the kind of innovation the field requires to conquer the most formidable cancer cases and bring much-needed relief to our patients."
The implications of this research are far-reaching. By identifying a new class of cancer-specific antigens derived from alternative RNA splicing, the UCSF team has provided a powerful new tool for developing immunotherapies. This could lead to more effective treatments for a wider range of cancers, particularly those that have historically been resistant to current therapeutic modalities. The ability to target tumor heterogeneity, a major obstacle in cancer treatment, is also a significant outcome of this research. As the scientific community continues to unravel the complexities of cancer, discoveries like these offer a beacon of hope and a testament to the relentless pursuit of innovative solutions in the battle against this devastating disease.
